Mahmoud Sharaf, MD
Cardiovascular Disease · Sioux Falls, SDNPI 1356677447
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.6%), food and beverage and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 62.1% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $7,402 and has fallen 97.3% since, to $198 in 2025.
Across 197 payments — averaging $53.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Boehringer Ingelheim$799
- Pfizer$456
- Johnson & Johnson$390
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$262
- Actelion Pharmaceuticals US, Inc.$256
- plus $2K from 23 others
What the payments were for
- Travel & lodging$5,45352%
- Food & beverage$5,07148%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 45 | $6,552 |
| Boehringer Ingelheim | 31 | $799 |
| Pfizer | 26 | $456 |
| Johnson & Johnson | 11 | $390 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $262 |
| Actelion Pharmaceuticals US, Inc. | 7 | $256 |
| Merck | 7 | $193 |
| AstraZeneca | 7 | $179 |
| E.r. Squibb & Sons, L.L.C. | 12 | $176 |
| Boston Scientific | 3 | $132 |
| Bayer | 2 | $112 |
| Inari Medical, Inc. | 2 | $111 |
| Abbott | 5 | $107 |
| Bard Peripheral Vascular, Inc. | 1 | $97 |
| Lantheus Medical Imaging, Inc. | 1 | $91 |
| Edwards Lifesciences | 1 | $87 |
| Acist Medical Systems, Inc. | 1 | $86 |
| Novartis | 6 | $84 |
| Astellas Pharma US Inc | 1 | $83 |
| Amgen | 2 | $82 |
| Sanofi-aventis U.S. LLC | 4 | $61 |
| Lexicon Pharmaceuticals, Inc. | 2 | $37 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Bracco Diagnostics Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $18 |
| Terumo Medical Corporation | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Baxter Healthcare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,559 in reported general payments places this provider in the 80th percentile of 33 cardiovascular disease providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 640 | $458,158 |
| EntrestoSacubitril/Valsartan | 318 | $230,764 |
| XareltoRivaroxaban | 201 | $136,690 |
| Repatha SureclickEvolocumab | 84 | $51,026 |
| JardianceEmpagliflozin | 42 | $31,842 |
| BrilintaTicagrelor | 30 | $21,548 |
| FarxigaDapagliflozin Propanediol | 27 | $18,990 |
| Praluent PenAlirocumab | 28 | $13,732 |
| MultaqDronedarone Hcl | 14 | $10,425 |
| Metoprolol Succinate | 1,174 | $9,388 |
| Ranolazine ErRanolazine | 90 | $8,368 |
| SotalolSotalol Hcl | 382 | $5,329 |
| Varenicline Tartrate | 15 | $4,255 |
| Atorvastatin Calcium | 435 | $2,871 |
| ClopidogrelClopidogrel Bisulfate | 511 | $2,698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $456 | $458,158640 claims |
| NovartisEntresto | $84 | $230,764318 claims |
| Johnson & JohnsonXarelto | $390 | $136,690201 claims |
| AstraZenecaBrilinta, Farxiga | $179 | $40,53857 claims |
| Boehringer IngelheimJardiance | $799 | $31,84242 claims |
| Sanofi-aventis U.S. LLCMultaq | $61 | $10,42514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 33 cardiovascular disease providers in South Dakota.
Other cardiovascular disease in Sioux Falls
- Naveen RajpurohitSioux Falls$68K
- Kevin VaskaSioux Falls$24K
- Udit BhatnagarSioux Falls$19K
- John BacharachSioux Falls$18K
- Maria StysSioux Falls$3K
- Christopher PaaSioux Falls$3K
- Richard ClarkSioux Falls$2K
- Amjad Panickaveettil Mohamed BasheerSioux Falls$1K
- Fawzi AmeerSioux Falls$1K
- Sherrie BrooksSioux Falls$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.